Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to determine the optimal dose of remifentanil that can prevent the complications associated with the removal of LMA without delaying emergence.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sangjin Park
• Treatments: Remifentanil

Criteria

Inclusion Criteria:

• American Society of Anesthesiologists physical status 1 or 2

• undergoing lower extremity surgery under general anesthesia

Exclusion Criteria:

• suspected difficult airways

• respiratory disease (chronic obstructive pulmonary disease, upper respiratory infection)

• body mass index > 30 kg/m2

• allergies to the study drugs

• a history of gastric reflux